THE EVALUATION OF IMMUNOGENIC POTENTIAL OF VARIOUS MEDICATIONS OF INSULIN

Abstract

The article presents a review of publications implemented with the purpose to characterize immunogenic potential of medications of insulin: from preparations of animal origin to modern genetically engineered products. The review is presented concerning regulative requirements regulating control of insulin products safety. It is established that during evaluation of safety of insulin products the main attention is focused on issues of immunogenicity. The analysis of publications from open access in information database MEDLINE (Pubmed) was carried out, permitting to characterize immunogenic potential of insulin preparations. On balance, the review included 17 articles according the results of selection. It is established that information about immunogenic potential of insulin products is contradictory enough that can be determined by both characteristics of studies and technological particularities of production of medicinal insulin products. The modern preparations of analogs of insulin are in general comparative by their safety characteristics with medicinal preparations of human genetically engineered insulin. Among analogs of insulin the most immunogenic potential is specific to aspart and glargin. The cases of development of cross-reactive antibodies between various medicinal preparations of insulin are observed.